NanoViricides Prepares Phase II MPox Trial in DRC, Seeks Orphan Drug Benefits
NanoViricides to begin Phase II trial of NV-387 for MPox Clade I in the DRC in early April after CRO site preparations and staff training. The company applied for FDA orphan drug designation, potentially unlocking fee waivers, R&D credits and tens of millions in exclusivity benefits.
1. Phase II Trial Launch and Logistics
NanoViricides plans to initiate its Phase II clinical trial of NV-387 for MPox Clade I in the Democratic Republic of Congo in early April. Site preparations and staff training are being conducted by Om Sai Clinical Research Pvt. Ltd., with patient enrollment and dosing to follow completion of training.
2. Orphan Drug Designation and Economic Impact
The company has applied for FDA orphan drug designation for NV-387 to treat MPox, which could provide benefits such as waived regulatory fees, R&D tax credits and extended marketing exclusivity. These advantages are estimated to add tens of millions of dollars in economic value.
3. Market Opportunity against MPox
No approved treatments exist for MPox Clade I and US Strategic National Stockpile contracts for smallpox drugs total several hundred million dollars. Success in Phase II could position NV-387 as a primary pandemic response candidate and open sizable government stockpiling opportunities.
4. Mechanism and Preclinical Results
NV-387 functions as a host-mimetic by mimicking sulfated proteoglycans, trapping orthopoxviruses and preventing cell infection. Animal-model studies showed efficacy comparable to tecovirimat in both skin and lung infection models, with low risk of viral escape due to its biomimetic design.